Acurx Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

SHARE-BASED COMPENSATION - (Details)

SHARE-BASED COMPENSATION - (Details)	1 Months Ended											3 Months Ended		6 Months Ended	9 Months Ended
SHARE-BASED COMPENSATION - (Details)	Apr. 30, 2026 director employee $ / shares shares	Feb. 28, 2025 USD ($) $ / shares shares	Jan. 31, 2025 $ / shares shares	Jun. 30, 2024 $ / shares shares	Feb. 29, 2024 $ / shares shares	Jun. 30, 2023 $ / shares shares	Feb. 28, 2023 $ / shares shares	Apr. 30, 2022 $ / shares shares	Jan. 31, 2022 $ / shares shares	Jul. 31, 2021 $ / shares shares	Jun. 30, 2021 $ / shares shares	Sep. 30, 2026 USD ($) $ / shares shares	Sep. 30, 2025 USD ($)	Jun. 30, 2026	Sep. 30, 2026 USD ($) $ / shares shares	Sep. 30, 2025 USD ($)	Dec. 31, 2025 USD ($)
Share-based compensation
Stock options granted (in shares)															120,850
Grant exercise price (in dollars per share) \| $ / shares															$ 2.36
Intrinsic value of stock option \| $												$ 0			$ 0		$ 0
2021 Equity Incentive Plan
Share-based compensation
Share based compensation expense \| $												$ 208,169	$ 294,793		$ 666,993	$ 952,607
Common stock shares reserved												425,732			425,732
Common stock shares available (in shares)												106,947			106,947
Total share options granted to date															348,625
Total compensation expense not yet recognized \| $												$ 510,894			$ 510,894
Weighted average vesting period														1 year 6 months 18 days
Weighted average grant date fair value \| $ / shares												$ 45.61			$ 45.61
2021 Equity Incentive Plan \| June 2021
Share-based compensation
Stock options granted (in shares)											40,375
Grant exercise price (in dollars per share) \| $ / shares											$ 125.2
2021 Equity Incentive Plan \| July 2021
Share-based compensation
Stock options granted (in shares)										77,500
Grant exercise price (in dollars per share) \| $ / shares										$ 123.6
2021 Equity Incentive Plan \| January 2022
Share-based compensation
Share based compensation expense \| $																6,317
Stock options granted (in shares)									4,000
Grant exercise price (in dollars per share) \| $ / shares									$ 88.8
2021 Equity Incentive Plan \| April 2022
Share-based compensation
Share based compensation expense \| $																7,170
Stock options granted (in shares)								1,500
Grant exercise price (in dollars per share) \| $ / shares								$ 75.8
2021 Equity Incentive Plan \| February 2023
Share-based compensation
Share based compensation expense \| $													109,521		$ 73,014	328,563
Stock options granted (in shares)							23,375
Grant exercise price (in dollars per share) \| $ / shares							$ 68.2
2021 Equity Incentive Plan \| June 2023
Share-based compensation
Stock options granted (in shares)						2,500
Grant exercise price (in dollars per share) \| $ / shares						$ 55
2021 Equity Incentive Plan \| February 2024
Share-based compensation
Share based compensation expense \| $												$ 183,713	183,713		551,139	551,139
Stock options granted (in shares)					41,750
Grant exercise price (in dollars per share) \| $ / shares					$ 63
2021 Equity Incentive Plan \| June 2024
Share-based compensation
Share based compensation expense \| $																55,260
Stock options granted (in shares)				3,000
Grant exercise price (in dollars per share) \| $ / shares				$ 47.6
2021 Equity Incentive Plan \| January 2025
Share-based compensation
Share based compensation expense \| $												1,560	$ 1,559		4,680	$ 4,158
Stock options granted (in shares)			1,500
Grant exercise price (in dollars per share) \| $ / shares			$ 15.54
2021 Equity Incentive Plan \| January 2025 \| Employee
Share-based compensation
Stock options granted (in shares)			1,500
Grant exercise price (in dollars per share) \| $ / shares			$ 15.54
Vesting term of options			36 months
2021 Equity Incentive Plan \| February 2025
Share-based compensation
Stock options granted (in shares)		32,275
Grant exercise price (in dollars per share) \| $ / shares		$ 15.96
2021 Equity Incentive Plan \| February 2025 \| Employee
Share-based compensation
Share based compensation expense \| $		$ 413,120
Stock options granted (in shares)		32,275
Grant exercise price (in dollars per share) \| $ / shares		$ 15.96
2021 Equity Incentive Plan \| April 2026
Share-based compensation
Share based compensation expense \| $												$ 22,896			$ 38,160
Stock options granted (in shares)	120,850	120,850
Grant exercise price (in dollars per share) \| $ / shares	$ 2.36	$ 2.36
2021 Equity Incentive Plan \| April 2026 \| Employee
Share-based compensation
Number of employees received stock \| employee	4
Vesting term of options	36 months
2021 Equity Incentive Plan \| April 2026 \| Directors
Share-based compensation
Number of Directors received stock \| director	5
Vesting term of options	1 year